The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Paolo F. Caimi; Kirit M. Ardeshna; Erin Reid; Weiyun Ai; Matthew Lunning; Jasmine Zain; Melhem Solh; Brad S. Kahl; Mehdi Hamadani

doi:10.1016/j.clml.2021.11.005

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Ai, Matthew Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.

Original language	English (US)
Pages (from-to)	e335-e339
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/j.clml.2021.11.005
State	Published - May 2022

Keywords

CAR-T cell failures
Diffuse large B cell lymphoma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2021.11.005

Cite this

@article{eb535a0ce7014dfdb572d1136231ffc7,

title = "The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy",

abstract = "Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.",

keywords = "CAR-T cell failures, Diffuse large B cell lymphoma",

author = "Caimi, {Paolo F.} and Ardeshna, {Kirit M.} and Erin Reid and Weiyun Ai and Matthew Lunning and Jasmine Zain and Melhem Solh and Kahl, {Brad S.} and Mehdi Hamadani",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2022",

month = may,

doi = "10.1016/j.clml.2021.11.005",

language = "English (US)",

volume = "22",

pages = "e335--e339",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

AU - Caimi, Paolo F.

AU - Ardeshna, Kirit M.

AU - Reid, Erin

AU - Ai, Weiyun

AU - Lunning, Matthew

AU - Zain, Jasmine

AU - Solh, Melhem

AU - Kahl, Brad S.

AU - Hamadani, Mehdi

PY - 2022/5

Y1 - 2022/5

N2 - Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.

AB - Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.

KW - CAR-T cell failures

KW - Diffuse large B cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85122947297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122947297&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.11.005

DO - 10.1016/j.clml.2021.11.005

M3 - Article

C2 - 35034868

AN - SCOPUS:85122947297

SN - 2152-2650

VL - 22

SP - e335-e339

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 5

ER -

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this